procalcitonin
pct
hormokin
approv
food
drug
agenc
biomark
sepsi
found
use
prognost
biomark
febril
neutropen
patient
document
infecti
complic
major
caus
morbid
mortal
febril
neutropen
patient
asct
fever
therefor
frequent
treat
antibiot
howev
unnecessari
use
antibiot
treatment
harbor
risk
evolut
drug
resist
bacteria
clostridium
difficil
infect
previous
report
high
resourc
util
associ
fever
engraft
syndrom
es
follow
autolog
stem
cell
transplant
asct
median
hospit
patient
develop
es
day
longer
without
es
patient
also
incur
averag
addit
cost
patient
multipl
myeloma
mm
risk
develop
es
follow
asct
patient
develop
complic
high
incid
attribut
prior
use
bortezomib
due
associ
hypogammaglobulinemia
mm
patient
also
increas
risk
infect
abil
differenti
fever
bacteri
infect
fever
es
mm
patient
therefor
greatli
need
set
evalu
util
pct
biomark
differenti
bacteri
infect
es
mm
patient
follow
asct
march
septemb
pct
protein
crp
level
obtain
febril
patient
asct
met
spitzer
maiolino
criteria
pct
measur
use
kryptor
bioanalys
via
immunofluoresc
assay
lower
detect
limit
ngml
valu
ngml
highli
suggest
system
infect
sever
local
infect
patient
demograph
clinic
laboratori
data
diagnosi
treatment
histori
collect
electron
medic
record
studi
approv
institut
review
board
new
york
medic
collegewestchest
medic
center
fifteen
patient
develop
es
follow
asct
clinic
characterist
shown
tabl
median
age
percent
men
autolog
peripher
blood
stem
cell
mobil
use
plerixafor
mgkg
transplant
prepar
regimen
consist
case
intraven
melphalan
patient
receiv
start
day
prophylact
ciprofloxacin
fluconazol
acyclovir
neutropenia
symptom
onset
es
occur
day
prior
day
follow
begin
neutrophil
recoveri
day
post
transplant
fever
last
day
median
work
bacteri
infect
neg
one
patient
time
engraft
one
patient
escherichia
coli
bacteremia
bacteri
infect
observ
follow
engraft
hospit
discharg
crp
level
elev
patient
median
rang
norm
mgdl
pct
elev
bacteremia
patient
ngml
remain
ngml
median
rang
observ
pct
cutoff
ngml
might
adjunct
biomark
identifi
patient
suffer
fever
associ
es
follow
asct
pct
guid
algorithm
may
limit
durat
antibiot
reduc
advers
event
prevent
emerg
antimicrobi
resist
larg
random
control
trial
compar
pct
guid
antimicrobi
therapi
vs
standard
care
limit
unnecessari
exposur
antimicrobi
immunocompromis
asct
recipi
warrant
noth
report
